where T and B are the tapered and baseline doses, D is the time in months from the most recent month at the baseline dose to the earliest month at the tapered dose, ln() is the natural logarithm function, and exp() is its inverse. The formula computes the monthly percent dose reduction with higher values indicating more rapid dose reduction and a maximum of 100, signifying a 100% dose reduction from one study month to the next.
For patients classified as tapering, we used a four-step process to identify the maximum velocity. The first step was to compute an array of up to 21 velocities based on comparisons of all possible baseline and tapering doses across the seven-month follow-up period, beginning with the six follow-up periods (F1-F6) relative to the baseline period (B) and continuing with the five latest follow-up periods (F2-F6) relative to the first follow-up period (F1), etc. (For patients with shorter follow-up periods due to censoring, the array of velocities was correspondingly smaller.)
The second step was to exclude all velocities that were derived from follow-up periods that occurred after any 60-day period during which the average daily dose increased by 10% or more above the baseline dose. (As above, we classified these patients as having an "unstable dose" during these periods.) We excluded velocity calculations based on months after dose instability because we observed very fast velocities in instances when the dispensed MME during a 60-day periods dropped precipitously after a transient increase in average daily dose above the baseline line dose. After excluding velocities after periods of dose instability, the remaining velocities all derived from period-to-period calculations during the period of dose reduction among tapering patients.
The third step was to exclude all velocity measurements after 60-day periods when the average daily dose was ≤50 MME. The rationale for this exclusion is that small absolute changes in daily doses below 50 MME may be associated with large percentage changes in month-to-month dose reduction.
In the fourth and final step, we selected the maximum velocity from the remaining velocities. This measure captures the maximum month-to-month percentage change in average daily dose among tapering patients during the tapering period and when the average daily dose was ≥50 MME. 
